* The newest monoclonal antibody, ipilimumab (Yervoy), is a targeted therapy for late-stage (metastatic) melanoma and is the first drug shown to prolong life in patients with this condition.
* The drug's most common adverse effects include fatigue, diarrhea, pruritus, rash, and colitis.
* Ipilimumab can have serious and even life-threatening immune-mediated adverse effects, such as enterocolitis, hepatitis, dermatitis, neuropathy, and endocrinopathy.
Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: firstname.lastname@example.org.